Combining PI3K/AKT inhibitors with agents that restore p53 function could produce a dual inhibitory effect on cancer cell migration (Abraham and O’Neill, 2014; Singh et al., 2002; Song et al., 2015; Turner et al., 2013). Here, AKT1 is linked to cancer.